INHIBIKASE THERAPEUTICS INC

Inhibikase’s insider option buys signal confidence in its kinase inhibitor pipeline and a bullish outlook for future valuation and reimbursement opportunities.

Insider sale by IKT’s director shows confidence, not distress. Learn how the move reflects the company’s neuro‑degeneration pipeline, regulatory prospects and upside for investors.